Abstract
Biologic agents may satisfy an unmet clinical need for treatment of refractory autoimmune hepatitis. The goals of this review are to present the types and results of biologic therapy for refractory autoimmune hepatitis, indicate opportunities to improve and expand biologic treatment, and encourage comparative clinical trials. English abstracts were identified in PubMed by multiple search terms. Full-length articles were selected for review, and secondary and tertiary bibliographies were developed. Rituximab (monoclonal antibodies against CD20 on B cells), infliximab (monoclonal antibodies against tumor necrosis factor-alpha), low-dose recombinant interleukin 2 (regulatory T cell promoter), and belimumab (monoclonal antibodies against B cell activating factor) have induced laboratory improvement in small cohorts with refractory autoimmune hepatitis. Ianalumab (monoclonal antibodies against the receptor for B cell activating factor) is in clinical trial. These agents target critical pathogenic pathways, but they may also have serious side effects. Blockade of the B cell activating factor or its receptors may disrupt pivotal B and T cell responses, and recombinant interleukin 2 complexed with certain interleukin 2 antibodies may selectively expand the regulatory T cell population. A proliferation-inducing ligand that enhances T cell proliferation and survival is an unevaluated, potentially pivotal, therapeutic target. Fully human antibodies, expanded target options, improved targeting precision, more effective delivery systems, and biosimilar agents promise to improve efficacy, safety, and accessibility. In conclusion, biologic agents target key pathogenic pathways in autoimmune hepatitis, and early experiences in refractory disease encourage clarification of the preferred target, rigorous clinical trial, and comparative evaluations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Longhi MS, Ma Y, Mieli-Vergani G, Vergani D. Aetiopathogenesis of autoimmune hepatitis. J Autoimmun. 2010;34:7–14.
Czaja AJ. Transitioning from idiopathic to explainable autoimmune hepatitis. Dig Dis Sci. 2015;60:2881–2900.
Mieli-Vergani G, Vergani D, Czaja AJ et al. Autoimmune hepatitis. Nat Rev Dis Primers. 2018;4:18017.
Kakiuchi T, Chesnut RW, Grey HM. B cells as antigen-presenting cells: the requirement for B cell activation. J Immunol. 1983;131:109–114.
Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature. 1985;314:537–539.
Constant S, Schweitzer N, West J, Ranney P, Bottomly K. B lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo. J Immunol. 1995;155:3734–3741.
Constant SL. B lymphocytes as antigen-presenting cells for CD4+ T cell priming in vivo. J Immunol. 1999;162:5695–5703.
Rivera A, Chen CC, Ron N, Dougherty JP, Ron Y. Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations. Int Immunol. 2001;13:1583–1593.
Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res. 2003;63:2836–2843.
Salinas GF, Braza F, Brouard S, Tak PP, Baeten D. The role of B lymphocytes in the progression from autoimmunity to autoimmune disease. Clin Immunol. 2013;146:34–45.
Hamilton JA, Hsu HC, Mountz JD. Role of production of type I interferons by B cells in the mechanisms and pathogenesis of systemic lupus erythematosus. Discov Med. 2018;25:21–29.
Bao Y, Liu X, Han C et al. Identification of IFN-gamma-producing innate B cells. Cell Res. 2014;24:161–176.
Olalekan SA, Cao Y, Hamel KM, Finnegan A. B cells expressing IFN-gamma suppress Treg-cell differentiation and promote autoimmune experimental arthritis. Eur J Immunol. 2015;45:988–998.
Fillatreau S. B cells and their cytokine activities implications in human diseases. Clin Immunol. 2018;186:26–31.
Menard LC, Minns LA, Darche S et al. B cells amplify IFN-gamma production by T cells via a TNF-alpha-mediated mechanism. J Immunol. 2007;179:4857–4866.
Yu M, Wen S, Wang M et al. TNF-alpha-secreting B cells contribute to myocardial fibrosis in dilated cardiomyopathy. J Clin Immunol. 2013;33:1002–1008.
Opata MM, Ye Z, Hollifield M, Garvy BA. B cell production of tumor necrosis factor in response to Pneumocystis murina infection in mice. Infect Immun. 2013;81:4252–4260.
Longhi MS, Ma Y, Bogdanos DP et al. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol. 2004;41:31–37.
Liberal R, Grant CR, Longhi MS, Mieli-Vergani G, Vergani D. Regulatory T cells: mechanisms of suppression and impairment in autoimmune liver disease. IUBMB Life. 2015;67:88–97.
Longhi MS, Mieli-Vergani G, Vergani D. Regulatory T cells in autoimmune hepatitis: an updated overview. J Autoimmun. 2021;119:102619.
Mack CL, Adams D, Assis DN et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology. 2020;72:671–722.
Jones D, Manns MP, Terracciano L, Torbenson M, Vierling JM. Unmet needs and new models for future trials in autoimmune hepatitis. Lancet Gastroenterol Hepatol. 2018;3:363–370.
Dyson JK, De Martin E, Dalekos GN et al. Review article: unanswered clinical and research questions in autoimmune hepatitis-conclusions of the International Autoimmune Hepatitis Group Research Workshop. Aliment Pharmacol Ther. 2019;49:528–536.
Vierling JM, Kerkar N, Czaja AJ et al. Immunosuppressive treatment regimens in autoimmune hepatitis: systematic reviews and meta-analyses supporting American Association for the Study of Liver Diseases guidelines. Hepatology. 2020;72:753–769.
Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov. 2008;7:21–39.
Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med. 2013;11:88.
Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015;20:122–128.
Anselmo AC, Gokarn Y, Mitragotri S. Non-invasive delivery strategies for biologics. Nat Rev Drug Discov. 2019;18:19–40.
Xiao Q, Li X, Li Y et al. Biological drug and drug delivery-mediated immunotherapy. Acta Pharm Sin B. 2021;11:941–960.
Prieto-Pena D, Dasgupta B. Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update. Pol Arch Intern Med. 2021;131:171–181.
Selvarajah V, Montano-Loza AJ, Czaja AJ. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Aliment Pharmacol Ther. 2012;36:691–707.
Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435–445.
Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant. 2006;6:859–866.
Liossis SN, Sfikakis PP. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin Immunol. 2008;127:280–285.
Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat Rev Immunol. 2010;10:236–247.
Beland K, Marceau G, Labardy A, Bourbonnais S, Alvarez F. Depletion of B cells induces remission of autoimmune hepatitis in mice through reduced antigen presentation and help to T cells. Hepatology. 2015;62:1511–1523.
Santos ES, Arosemena LR, Raez LE, O’Brien C, Regev A. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. Liver Int. 2006;26:625–629.
Evans JT, Shepard MM, Oates JC, Self SE, Reuben A. Rituximab-responsive cryoglobulinemic glomerulonephritis in a patient with autoimmune hepatitis. J Clin Gastroenterol. 2008;42:862–863.
Barth E, Clawson J. A case of autoimmune hepatitis treated with rituximab. Case Rep Gastroenterol. 2010;4:502–509.
Carey EJ, Somaratne K, Rakela J. Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome. Rev Med Chil. 2011;139:1484–1487.
D’Agostino D, Costaguta A, Alvarez F. Successful treatment of refractory autoimmune hepatitis with rituximab. Pediatrics. 2013;132:e526-530.
Burak KW, Swain MG, Santodomino-Garzon T et al. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol. 2013;27:273–280.
Al-Busafi SA, Michel RP, Deschenes M. Rituximab for refractory autoimmune hepatitis: a case report. Arab J Gastroenterol. 2013;14:135–138.
Jarasvaraparn C, Imran H, Siddiqui A, Wilson F, Gremse DA. Association of autoimmune hepatitis type 1 in a child with Evans syndrome. World J Hepatol. 2017;9:1008–1012.
Than NN, Hodson J, Schmidt-Martin D et al. Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group. JHEP Rep. 2019;1:437–445.
Appanna GD, Pembroke TPI, Miners KL et al. Rituximab depletion of intrahepatic B cells to control refractory hepatic autoimmune overlap syndrome. QJM. 2019;112:793–795.
Lim TY, Martinez-Llordella M, Kodela E et al. Low-dose interleukin-2 for refractory autoimmune hepatitis. Hepatology. 2018;68:1649–1652.
Czaja AJ. Exploring the pathogenic role and therapeutic implications of interleukin 2 in autoimmune hepatitis. Dig Dis Sci. 2021;66:2493–2512.
Buitrago-Molina LE, Pietrek J, Noyan F, et al. Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis. J Autoimmun. 2021;117:102591.
Weiler-Normann C, Wiegard C, Schramm C, Lohse AW. A case of difficult-to-treat autoimmune hepatitis successfully managed by TNF-alpha blockade. Am J Gastroenterol. 2009;104:2877–2878.
Weiler-Normann C, Schramm C, Quaas A et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol. 2013;58:529–534.
Arvaniti P, Giannoulis G, Gabeta S, et al. Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis. JHEP Rep. 2020;2:100123.
Engel B, Taubert R, Jaeckel E, Manns MP. The future of autoimmune liver diseases - Understanding pathogenesis and improving morbidity and mortality. Liver Int. 2020;40:149–153.
Halliday N, Dyson JK, Thorburn D, Lohse AW, Heneghan MA. Review article: experimental therapies in autoimmune hepatitis. Aliment Pharmacol Ther. 2020;52:1134–1149.
Jang DI, Lee AH, Shin HY et al. The role of tumor necrosis factor alpha (TNF-alpha) in autoimmune disease and current TNF-alpha inhibitors in therapeutics. Int J Mol Sci. 2021;22:2719.
Lim H, Lee SH, Lee HT et al. Structural biology of the TNF-alpha antagonists used in the treatment of rheumatoid arthritis. Int J Mol Sci. 2018;19:768.
Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov. 2002;1:457–462.
Czaja AJ. Review article: targeting the B cell activation system in autoimmune hepatitis. Aliment Pharm Ther. 2021;54:902–922.
Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011:CD008794.
Chang C, Tanaka A, Bowlus C, Gershwin ME. The use of biologics in the treatment of autoimmune liver disease. Expert Opin Investig Drugs. 2020;29:385–398.
Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med. 1971;40:159–185.
Soloway RD, Summerskill WH, Baggenstoss AH et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972;63:820–833.
Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet. 1973;1:735–737.
Pratt DS, Flavin DP, Kaplan MM. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology. 1996;110:271–274.
Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus. 2005;14:s2-8.
Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol. 2005;39:819–825.
Hubener S, Oo YH, Than NN et al. Efficacy of 6-mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance. Clin Gastroenterol Hepatol. 2016;14:445–453.
Czaja AJ. Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis. Aliment Pharmacol Ther. 2020;51:1286–1304.
Allison AC. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology. 2000;47:63–83.
Czaja AJ. Drug choices in autoimmune hepatitis: Part B - nonsteroids. Expert Rev Gastroenterol Hepatol. 2012;6:617–635.
Nadler LM, Ritz J, Hardy R et al. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest. 1981;67:134–140.
Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 1988;7:711–717.
Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980;125:1678–1685.
Tedder TF, Streuli M, Schlossman SF, Saito H. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci U S A. 1988;85:208–212.
Kanzaki M, Shibata H, Mogami H, Kojima I. Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells. J Biol Chem. 1995;270:13099–13104.
Li H, Ayer LM, Lytton J, Deans JP. Store-operated cation entry mediated by CD20 in membrane rafts. J Biol Chem. 2003;278:42427–42434.
Bellosillo B, Villamor N, Lopez-Guillermo A et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood. 2001;98:2771–2777.
Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359–7368.
Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6:443–446.
Byrd JC, Kitada S, Flinn IW et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002;99:1038–1043.
Czaja AJ. Targeting apoptosis in autoimmune hepatitis. Dig Dis Sci. 2014;59:2890–2904.
Tamaru M, Nishioji K, Kobayashi Y et al. Liver-infiltrating T lymphocytes are attracted selectively by IFN-inducible protein-10. Cytokine. 2000;12:299–308.
Nishioji K, Okanoue T, Itoh Y et al. Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes. Clin Exp Immunol. 2001;123:271–279.
Nishikawa H, Enomoto H, Iwata Y, et al. B-cell activating factor belonging to the tumor necrosis factor family and interferon-gamma-inducible protein-10 in autoimmune hepatitis. Medicine (Baltimore). 2016;95:e3194.
Nagayama K, Enomoto N, Miyasaka Y et al. Overexpression of interferon gamma-inducible protein 10 in the liver of patients with type I autoimmune hepatitis identified by suppression subtractive hybridization. Am J Gastroenterol. 2001;96:2211–2217.
Oo YH, Banz V, Kavanagh D et al. CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver. J Hepatol. 2012;57:1044–1051.
Antonelli A, Ferrari SM, Giuggioli D et al. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev. 2014;13:272–280.
Czaja AJ. Review article: Chemokines as orchestrators of autoimmune hepatitis and potential therapeutic targets. Aliment Pharmacol Ther. 2014;40:261–279.
Sfikakis PP, Souliotis VL, Fragiadaki KG et al. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol. 2007;123:66–73.
Tsuda M, Moritoki Y, Lian ZX et al. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology. 2012;55:512–521.
Stasi R, Cooper N, Del Poeta G et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood. 2008;112:1147–1150.
Saadoun D, Rosenzwajg M, Landau D et al. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood. 2008;111:5334–5341.
Vallerskog T, Gunnarsson I, Widhe M et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol. 2007;122:62–74.
Feuchtenberger M, Muller S, Roll P et al. Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Open Rheumatol J. 2008;2:81–88.
Bouaziz JD, Calbo S, Maho-Vaillant M et al. IL-10 produced by activated human B cells regulates CD4(+) T-cell activation in vitro. Eur J Immunol. 2010;40:2686–2691.
Bouaziz JD, Le Buanec H, Saussine A, Bensussan A, Bagot M. IL-10 producing regulatory B cells in mice and humans: state of the art. Curr Mol Med. 2012;12:519–527.
Tedder TF. B10 cells: a functionally defined regulatory B cell subset. J Immunol. 2015;194:1395–1401.
Wang L, Fu Y, Chu Y. Regulatory B cells. Adv Exp Med Biol. 2020;1254:87–103.
Lee KM, Stott RT, Zhao G et al. TGF-beta-producing regulatory B cells induce regulatory T cells and promote transplantation tolerance. Eur J Immunol. 2014;44:1728–1736.
Schroder C, Azimzadeh AM, Wu G et al. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol. 2003;12:19–28.
Maloney DG, Liles TM, Czerwinski DK et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84:2457–2466.
Sidner RA, Book BK, Agarwal A et al. In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. Hum Antibodies. 2004;13:55–62.
Gong Q, Ou Q, Ye S et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. 2005;174:817–826.
Mei HE, Frolich D, Giesecke C et al. Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab. Blood. 2010;116:5181–5190.
Ghielmini M, Rufibach K, Salles G et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol. 2005;16:1675–1682.
Du FH, Mills EA, Mao-Draayer Y. Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Auto Immun Highlights. 2017;8:12.
Randall KL. Rituximab in autoimmune diseases. Aust Prescr. 2016;39:131–134.
Keystone E, Fleischmann R, Emery P et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56:3896–3908.
Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev. 2010;237:264–283.
van Vollenhoven RF, Emery P, Bingham CO 3rd et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72:1496–1502.
Bingham CO 3rd, Looney RJ, Deodhar A et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 2010;62:64–74.
Bearden CM, Agarwal A, Book BK et al. Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. Am J Transplant. 2005;5:50–57.
Buch MH, Smolen JS, Betteridge N et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:909–920.
Eisenberg RA, Jawad AF, Boyer J et al. Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol. 2013;33:388–396.
van Vollenhoven RF, Emery P, Bingham CO 3rd et al. Long-term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010;37:558–567.
Vugmeyster Y, Beyer J, Howell K et al. Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J Immunother. 2005;28:212–219.
Uchiyama S, Suzuki Y, Otake K et al. Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope. Cancer Sci. 2010;101:201–209.
Ahmadzadeh V, Farajnia S, Hosseinpour Feizi MA, Khavarinejad RA. Design, expression and characterization of a single chain anti-CD20 antibody; a germline humanized antibody derived from Rituximab. Protein Expr Purif. 2014;102:45–51.
Khoo YL, Cheah SH, Chong H. Humanization of chimeric anti-CD20 antibody by logical and bioinformatics approach with retention of biological activity. Immunotherapy. 2017;9:567–577.
Trabik YA, Moenes EM, Al-Ghobashy MA, Nebsen M, Ayad MF. Analytical comparability study of anti-CD20 monoclonal antibodies rituximab and obinutuzumab using a stability-indicating orthogonal testing protocol: Effect of structural optimization and glycoengineering. J Chromatogr B Analyt Technol Biomed Life Sci. 2020;1159:122359.
Tony HP, Burmester G, Schulze-Koops H et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther. 2011;13:R75.
Roberts DM, Jones RB, Smith RM et al. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun. 2015;57:60–65.
Furst DE. Serum immunoglobulins and risk of infection: how low can you go? Semin Arthritis Rheum. 2009;39:18–29.
Gottenberg JE, Ravaud P, Bardin T et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010;62:2625–2632.
Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford). 2001;40:205–211.
Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis. 2002;61:883–888.
Agarwal A, Vieira CA, Book BK et al. Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses. Am J Transplant. 2004;4:1357–1360.
Salmon JH, Cacoub P, Combe B, et al. Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry. RMD Open. 2015;1:e000034.
Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: past, present and future. Int Immunol. 2015;27:55–62.
Kaymakcalan Z, Sakorafas P, Bose S et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol. 2009;131:308–316.
Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214:149–160.
Mitoma H, Horiuchi T, Hatta N et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology. 2005;128:376–392.
Danese S. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker. Dig Liver Dis. 2008;40:S225-228.
Melsheimer R, Geldhof A, Apaolaza I, Schaible T. Remicade((R)) (infliximab): 20 years of contributions to science and medicine. Biologics. 2019;13:139–178.
Peck R, Brockhaus M, Frey JR. Cell surface tumor necrosis factor (TNF) accounts for monocyte- and lymphocyte-mediated killing of TNF-resistant target cells. Cell Immunol. 1989;122:1–10.
Horiuchi T, Morita C, Tsukamoto H et al. Increased expression of membrane TNF-alpha on activated peripheral CD8+ T cells in systemic lupus erythematosus. Int J Mol Med. 2006;17:875–879.
Mehta AK, Gracias DT, Croft M. TNF activity and T cells. Cytokine. 2018;101:14–18.
Caron G, Delneste Y, Aubry JP et al. Human NK cells constitutively express membrane TNF-alpha (mTNFalpha) and present mTNFalpha-dependent cytotoxic activity. Eur J Immunol. 1999;29:3588–3595.
Falvo JV, Tsytsykova AV, Goldfeld AE. Transcriptional control of the TNF gene. Curr Dir Autoimmun. 2010;11:27–60.
Fishman M. Cytolytic activities of activated macrophages versus paraformaldehyde-fixed macrophages; soluble versus membrane-associated TNF. Cell Immunol. 1991;137:164–174.
Sedger LM, McDermott MF. TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future. Cytokine Growth Factor Rev. 2014;25:453–472.
Black RA, Rauch CT, Kozlosky CJ et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997;385:729–733.
Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford). 2010;49:1215–1228.
Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. 1995;5:392–399.
Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334:1717–1725.
Chan FK, Chun HJ, Zheng L et al. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science. 2000;288:2351–2354.
MacEwan DJ. TNF ligands and receptors–a matter of life and death. Br J Pharmacol. 2002;135:855–875.
Brenner D, Blaser H, Mak TW. Regulation of tumour necrosis factor signalling: live or let die. Nat Rev Immunol. 2015;15:362–374.
Nagar M, Jacob-Hirsch J, Vernitsky H et al. TNF activates a NF-kappaB-regulated cellular program in human CD45RA- regulatory T cells that modulates their suppressive function. J Immunol. 2010;184:3570–3581.
Eissner G, Kirchner S, Lindner H et al. Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J Immunol. 2000;164:6193–6198.
Eissner G, Kolch W, Scheurich P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev. 2004;15:353–366.
Lee WH, Seo D, Lim SG, Suk K. Reverse signaling of tumor necrosis factor superfamily proteins in macrophages and microglia: superfamily portrait in the neuroimmune interface. Front Immunol. 2019;10:262.
Juhasz K, Buzas K, Duda E. Importance of reverse signaling of the TNF superfamily in immune regulation. Expert Rev Clin Immunol. 2013;9:335–348.
Kaufman DR, Choi Y. Signaling by tumor necrosis factor receptors: pathways, paradigms and targets for therapeutic modulation. Int Rev Immunol. 1999;18:405–427.
Chen X, Subleski JJ, Kopf H et al. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells. J Immunol. 2008;180:6467–6471.
Chen X, Oppenheim JJ. The phenotypic and functional consequences of tumour necrosis factor receptor type 2 expression on CD4(+) FoxP3(+) regulatory T cells. Immunology. 2011;133:426–433.
Chen X, Hamano R, Subleski JJ et al. Expression of costimulatory TNFR2 induces resistance of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells. J Immunol. 2010;185:174–182.
Chen X, Oppenheim JJ. Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity. FEBS Lett. 2011;585:3611–3618.
Tartaglia LA, Ayres TM, Wong GH, Goeddel DV. A novel domain within the 55 kd TNF receptor signals cell death. Cell. 1993;74:845–853.
Puimege L, Libert C, Van Hauwermeiren F. Regulation and dysregulation of tumor necrosis factor receptor-1. Cytokine Growth Factor Rev. 2014;25:285–300.
Galluzzi L, Vitale I, Abrams JM et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 2012;19:107–120.
Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10:45–65.
Rothe J, Lesslauer W, Lotscher H et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature. 1993;364:798–802.
Pfeffer K, Matsuyama T, Kundig TM, et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell. 1993;73:457–467.
Stoelcker B, Ruhland B, Hehlgans T et al. Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature. Am J Pathol. 2000;156:1171–1176.
Grell M, Douni E, Wajant H et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 1995;83:793–802.
Pinckard JK, Sheehan KC, Arthur CD, Schreiber RD. Constitutive shedding of both p55 and p75 murine TNF receptors in vivo. J Immunol. 1997;158:3869–3873.
Xanthoulea S, Pasparakis M, Kousteni S et al. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J Exp Med. 2004;200:367–376.
Kim EY, Teh HS. TNF type 2 receptor (p75) lowers the threshold of T cell activation. J Immunol. 2001;167:6812–6820.
Kim EY, Priatel JJ, Teh SJ, Teh HS. TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo. J Immunol. 2006;176:1026–1035.
Chatzidakis I, Fousteri G, Tsoukatou D, Kollias G, Mamalaki C. An essential role for TNF in modulating thresholds for survival, activation, and tolerance of CD8+ T cells. J Immunol. 2007;178:6735–6745.
Chatzidakis I, Mamalaki C. T cells as sources and targets of TNF: implications for immunity and autoimmunity. Curr Dir Autoimmun. 2010;11:105–118.
Chen X, Baumel M, Mannel DN, Howard OM, Oppenheim JJ. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol. 2007;179:154–161.
Grinberg-Bleyer Y, Saadoun D, Baeyens A et al. Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. J Clin Invest. 2010;120:4558–4568.
Ehrenstein MR, Evans JG, Singh A et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med. 2004;200:277–285.
Valencia X, Stephens G, Goldbach-Mansky R et al. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood. 2006;108:253–261.
Ma HL, Napierata L, Stedman N et al. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum. 2010;62:430–440.
Wu AJ, Hua H, Munson SH, McDevitt HO. Tumor necrosis factor-alpha regulation of CD4+CD25+ T cell levels in NOD mice. Proc Natl Acad Sci U S A. 2002;99:12287–12292.
Mougiakakos D, Johansson CC, Jitschin R, Bottcher M, Kiessling R. Increased thioredoxin-1 production in human naturally occurring regulatory T cells confers enhanced tolerance to oxidative stress. Blood. 2011;117:857–861.
Czaja AJ. Nature and implications of oxidative and nitrosative stresses in autoimmune hepatitis. Dig Dis Sci. 2016;61:2784–2803.
Kleijwegt FS, Laban S, Duinkerken G et al. Critical role for TNF in the induction of human antigen-specific regulatory T cells by tolerogenic dendritic cells. J Immunol. 2010;185:1412–1418.
Aggarwal BB, Shishodia S, Takada Y, et al. TNF blockade: an inflammatory issue. Ernst Schering Res Found Workshop. 2006:161–186.
Van Hauwermeiren F, Vandenbroucke RE, Libert C. Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1. Cytokine Growth Factor Rev. 2011;22:311–319.
Maggiore G, De Benedetti F, Massa M, Pignatti P, Martini A. Circulating levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in children with autoimmune hepatitis. J Pediatr Gastroenterol Nutr. 1995;20:23–27.
Thomas-Dupont P, Remes-Troche JM, Izaguirre-Hernandez IY et al. Elevated circulating levels of IL-21 and IL-22 define a cytokine signature profile in type 2 autoimmune hepatitis patients. Ann Hepatol. 2016;15:550–558.
Akberova D, Kiassov AP, Abdulganieva D. Serum cytokine levels and their relation to clinical features in patients with autoimmune liver diseases. J Immunol Res. 2017;2017:9829436.
Liang M, Liwen Z, Yun Z, Yanbo D, Jianping C. Serum Levels of IL-33 and correlation with IL-4, IL-17A, and hypergammaglobulinemia in patients with autoimmune hepatitis. Mediators Inflamm. 2018;2018:7964654.
Chaouali M, Ben Azaiez M, Tezeghdenti A et al. High levels of proinflammatory cytokines IL-6, IL-8, TNF-Alpha, IL-23, and IFN- in Tunisian patients with type 1 autoimmune hepatitis. Eur Cytokine Netw. 2020. https://doi.org/10.1684/ecn.2020.0450.
Iwamoto S, Kido M, Aoki N et al. TNF-alpha is essential in the induction of fatal autoimmune hepatitis in mice through upregulation of hepatic CCL20 expression. Clin Immunol. 2013;146:15–25.
Czaja AJ, Cookson S, Constantini PK et al. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology. 1999;117:645–652.
Cookson S, Constantini PK, Clare M et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology. 1999;30:851–856.
Bathgate AJ, Pravica V, Perrey C, Hayes PC, Hutchinson IV. Polymorphisms in tumour necrosis factor alpha, interleukin-10 and transforming growth factor beta1 genes and end-stage liver disease. Eur J Gastroenterol Hepatol. 2000;12:1329–1333.
Li S, Huang X, Zhong H et al. Tumour necrosis factor alpha (TNF-alpha) genetic polymorphisms and the risk of autoimmune liver disease: a meta-analysis. J Genet. 2013;92:617–628.
Qin B, Li J, Liang Y, Yang Z, Zhong R. The association between cytotoxic T lymphocyte associated antigen-4, Fas, tumour necrosis factor-alpha gene polymorphisms and autoimmune hepatitis: a meta-analysis. Dig Liver Dis. 2014;46:541–548.
Chaouali M, Azaiez MB, Tezeghdenti A et al. Association of TNF-alpha-308 polymorphism with susceptibility to autoimmune hepatitis in Tunisians. Biochem Genet. 2018;56:650–662.
Motawi TK, El-Maraghy SA, Sharaf SA, Said SE. Association of CARD10 rs6000782 and TNF rs1799724 variants with paediatric-onset autoimmune hepatitis. J Adv Res. 2019;15:103–110.
Zachou K, Rigopoulou EI, Tsikrikoni A et al. Autoimmune hepatitis type 1 and primary biliary cirrhosis have distinct bone marrow cytokine production. J Autoimmun. 2005;25:283–288.
Bittencourt PL, Palacios SA, Cancado EL et al. Autoimmune hepatitis in Brazilian patients is not linked to tumor necrosis factor alpha polymorphisms at position -308. J Hepatol. 2001;35:24–28.
Fan LY, Zhong RQ, Tu XQ, et al. [Genetic association of tumor necrosis factor (TNF)-alpha polymorphisms with primary biliary cirrhosis and autoimmune liver diseases in a Chinese population]. Zhonghua Gan Zang Bing Za Zhi. 2004;12:160–162.
de Boer YS, van Gerven NM, Zwiers A et al. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology. 2014;147:443–452.
Mendoza-Carrera F, Gastelum-Meza MA, Ramirez-Garcia J et al. No association of HLA-DRB1 and TNF alleles in Mexican patients with autoimmune hepatitis. Genes Immun. 2019;20:678–683.
Abbas AK, Benoist C, Bluestone JA et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol. 2013;14:307–308.
Mitoma H, Horiuchi T, Tsukamoto H et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 2008;58:1248–1257.
Scallon B, Cai A, Solowski N et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002;301:418–426.
Mitoma H, Horiuchi T, Tsukamoto H, Ueda N. Molecular mechanisms of action of anti-TNF-alpha agents - Comparison among therapeutic TNF-alpha antagonists. Cytokine. 2018;101:56–63.
Agnholt J, Kaltoft K. Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn’s disease. Cytokine. 2001;15:212–222.
Agnholt J, Kelsen J, Brandsborg B, Jakobsen NO, Dahlerup JF. Increased production of granulocyte-macrophage colony-stimulating factor in Crohn’s disease–a possible target for infliximab treatment. Eur J Gastroenterol Hepatol. 2004;16:649–655.
Kirman I, Whelan RL, Nielsen OH. Infliximab: mechanism of action beyond TNF-alpha neutralization in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2004;16:639–641.
Arijs I, De Hertogh G, Machiels K et al. Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment. Am J Gastroenterol. 2011;106:748–761.
Di Sabatino A, Pender SL, Jackson CL et al. Functional modulation of Crohn’s disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology. 2007;133:137–149.
Guo Y, Lu N, Bai A. Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update. Biomed Res Int. 2013;2013:581631.
ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease. Gut. 2002;50:206–211.
Rajanayagam J, Lewindon PJ. Infliximab as rescue therapy in paediatric autoimmune hepatitis. J Hepatol. 2013;59:908–909.
Bongartz T, Sutton AJ, Sweeting MJ et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–2285.
Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum. 2010;39:327–346.
Murdaca G, Spano F, Contatore M et al. Infection risk associated with anti-TNF-alpha agents: a review. Expert Opin Drug Saf. 2015;14:571–582.
Downey C. Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review. Int J Rheum Dis. 2016;19:536–550.
Liao H, Zhong Z, Liu Z, Zou X. Comparison of the risk of infections in different anti-TNF agents: a meta-analysis. Int J Rheum Dis. 2017;20:161–168.
Fernandez-Ruiz M, Aguado JM. Risk of infection associated with anti-TNF-alpha therapy. Expert Rev Anti Infect Ther. 2018;16:939–956.
Murdaca G, Negrini S, Pellecchio M et al. Update upon the infection risk in patients receiving TNF alpha inhibitors. Expert Opin Drug Saf. 2019;18:219–229.
Bruns H, Meinken C, Schauenberg P et al. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest. 2009;119:1167–1177.
Dommasch ED, Abuabara K, Shin DB et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64:1035–1050.
Lichtenstein GR, Rutgeerts P, Sandborn WJ et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107:1051–1063.
Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol. 2014;12:1443–1451.
Bjornsson ES, Gunnarsson BI, Grondal G et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2015;13:602–608.
French JB, Bonacini M, Ghabril M, Foureau D, Bonkovsky HL. Hepatotoxicity associated with the use of anti-TNF-alpha agents. Drug Saf. 2016;39:199–208.
Averbukh LD, Wu GY. Role of biologics in the development of autoimmune hepatitis: A review. J Clin Transl Hepatol. 2018;6:402–409.
Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010;2:256–265.
Zheng L, Fisher G, Miller RE et al. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature. 1995;377:348–351.
Via CS, Shustov A, Rus V et al. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol. 2001;167:6821–6826.
Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis. 2005;64:403–407.
Gessner JE, Heiken H, Tamm A, Schmidt RE. The IgG Fc receptor family. Ann Hematol. 1998;76:231–248.
Siberil S, Dutertre CA, Boix C et al. Molecular aspects of human FcgammaR interactions with IgG: functional and therapeutic consequences. Immunol Lett. 2006;106:111–118.
Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn’s disease. Drugs. 2004;64:1767–1777.
Marques M, Magro F, Cardoso H et al. Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis. Inflamm Bowel Dis. 2008;14:723–725.
Goujon C, Dahel K, Berard F et al. Autoimmune hepatitis in two psoriasis patients treated with inflixmab. J Am Acad Dermatol. 2010;63:e43-44.
Poulin Y, Therien G. Drug-induced hepatitis and lupus during infliximab treatment for psoriasis: case report and literature review. J Cutan Med Surg. 2010;14:100–104.
Cravo M, Silva R, Serrano M. Autoimmune hepatitis induced by infliximab in a patient with Crohn’s disease with no relapse after switching to adalimumab. Biodrugs. 2010;24:25–27.
Goldfeld DA, Verna EC, Lefkowitch J, Swaminath A. Infliximab-induced autoimmune hepatitis with successful switch to adalimumab in a patient with Crohn’s disease: the index case. Dig Dis Sci. 2011;56:3386–3388.
Doyle A, Forbes G, Kontorinis N. Autoimmune hepatitis during infliximab therapy for Crohn’s disease: a case report. J Crohns Colitis. 2011;5:253–255.
Subramaniam K, Chitturi S, Brown M, Pavli P. Infliximab-induced autoimmune hepatitis in Crohn’s disease treated with budesonide and mycophenolate. Inflamm Bowel Dis. 2011;17:E149-150.
van Casteren-Messidoro C, Prins G, van Tilburg A et al. Autoimmune hepatitis following treatment with infliximab for inflammatory bowel disease. J Crohns Colitis. 2012;6:630–631.
Dang LJ, Lubel JS, Gunatheesan S, Hosking P, Su J. Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis. Australas J Dermatol. 2014;55:75–79.
Rodrigues S, Lopes S, Magro F et al. Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: A single center report of 8 cases. World J Gastroenterol. 2015;21:7584–7588.
Wong F, Al Ibrahim B, Walsh J, Qumosani K. Infliximab-induced autoimmune hepatitis requiring liver transplantation. Clin Case Rep. 2019;7:2135–2139.
Jenkins A, Austin A, Hughes K, Sadowski B, Torres D. Infliximab-induced autoimmune hepatitis. BMJ Case Rep. 2021;14.
Mustafa Alikhan M, Mansoor E, Satyavada S, et al. Infliximab-Induced acute liver failure in a patient with Crohn's disease requiring orthotopic liver transplantation. ACG Case Rep J. 2021;8:e00586.
Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56:958–976.
Bonovas S, Fiorino G, Allocca M et al. Biologic therapies and risk of Infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2016;14:1385–1397.
Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874–881.
Hyams JS, Dubinsky MC, Baldassano RN et al. Infliximab Is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease. Gastroenterology. 2017;152:1901–1914.
Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 2007;56:1433–1439.
Alvisi P, Dipasquale V, Barabino A et al. Infections and malignancies risks related to TNF-alpha-blocking agents in pediatric inflammatory bowel diseases. Expert Rev Gastroenterol Hepatol. 2019;13:957–961.
Czaja AJ. Hepatocellular cancer and other malignancies in autoimmune hepatitis. Dig Dis Sci. 2013;58:1459–1476.
Arenas-Ramirez N, Woytschak J, Boyman O. Interleukin-2: biology, design and application. Trends Immunol. 2015;36:763–777.
Rozwarski DA, Gronenborn AM, Clore GM et al. Structural comparisons among the short-chain helical cytokines. Structure. 1994;2:159–173.
Reche PA. The tertiary structure of γc cytokines dictates receptor sharing. Cytokine. 2019;116:161–168.
Devos R, Plaetinck G, Cheroutre H, et al. Molecular cloning of human interleukin 2 cDNA and its expression in E. coli. Nucleic Acids Res. 1983;11:4307–4323.
Roifman CM, Mills GB, Chu M, Gelfand EW. Functional comparison of recombinant interleukin 2 (IL-2) with IL-2-containing preparations derived from cultured cells. Cell Immunol. 1985;95:146–156.
Rosenzwajg M, Lorenzon R, Cacoub P et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis. 2019;78:209–217.
Hartemann A, Bensimon G, Payan CA et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013;1:295–305.
Rosenzwajg M, Churlaud G, Mallone R et al. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. J Autoimmun. 2015;58:48–58.
Koreth J, Matsuoka K, Kim HT et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365:2055–2066.
He J, Zhang X, Wei Y et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med. 2016;22:991–993.
von Spee-Mayer C, Siegert E, Abdirama D et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann Rheum Dis. 2016;75:1407–1415.
Castela E, Le Duff F, Butori C et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol. 2014;150:748–751.
Saadoun D, Rosenzwajg M, Joly F et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011;365:2067–2077.
Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science. 2006;311:1924–1927.
Boyman O, Surh CD, Sprent J. Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. Expert Opin Biol Ther. 2006;6:1323–1331.
Spangler JB, Tomala J, Luca VC et al. Antibodies to interleukin-2 elicit selective T cell subset potentiation through distinct conformational mechanisms. Immunity. 2015;42:815–825.
Trotta E, Bessette PH, Silveria SL et al. A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism. Nat Med. 2018;24:1005–1014.
Owen DL, Mahmud SA, Vang KB et al. Identification of cellular sources of IL-2 needed for regulatory T cell development and homeostasis. J Immunol. 2018;200:3926–3933.
Nelson BH. IL-2, regulatory T cells, and tolerance. J Immunol. 2004;172:3983–3988.
Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol. 2004;4:665–674.
Taniguchi T, Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell. 1993;73:5–8.
Nelson BH, Willerford DM. Biology of the interleukin-2 receptor. Adv Immunol. 1998;70:1–81.
Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity. 2010;33:153–165.
Antov A, Yang L, Vig M, Baltimore D, Van Parijs L. Essential role for STAT5 signaling in CD25+CD4+ regulatory T cell homeostasis and the maintenance of self-tolerance. J Immunol. 2003;171:3435–3441.
Feng Y, Arvey A, Chinen T et al. Control of the inheritance of regulatory T cell identity by a cis element in the Foxp3 locus. Cell. 2014;158:749–763.
Chinen T, Kannan AK, Levine AG et al. An essential role for the IL-2 receptor in Treg cell function. Nat Immunol. 2016;17:1322–1333.
Tsuji-Takayama K, Suzuki M, Yamamoto M et al. The production of IL-10 by human regulatory T cells is enhanced by IL-2 through a STAT5-responsive intronic enhancer in the IL-10 locus. J Immunol. 2008;181:3897–3905.
Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas AK. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity. 1998;8:615–623.
Dai Z, Arakelov A, Wagener M, Konieczny BT, Lakkis FG. The role of the common cytokine receptor gamma-chain in regulating IL-2-dependent, activation-induced CD8+ T cell death. J Immunol. 1999;163:3131–3137.
Zheng L, Trageser CL, Willerford DM, Lenardo MJ. T cell growth cytokines cause the superinduction of molecules mediating antigen-induced T lymphocyte death. J Immunol. 1998;160:763–769.
Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12:180–190.
Boyman O, Cho JH, Sprent J. The role of interleukin-2 in memory CD8 cell differentiation. Adv Exp Med Biol. 2010;684:28–41.
Carter L, Fouser LA, Jussif J et al. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol. 2002;32:634–643.
Czaja AJ. Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. Autoimmunity. 2019;52:144–160.
Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105–2116.
Smylie MG. Use of immuno-oncology in melanoma. Curr Oncol. 2020;27:S51–S58.
Liberal R, Grant CR, Holder BS et al. In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression. Hepatology. 2015;62:863–875.
Saxena S, Nouri-Aria KT, Anderson MG, Eddleston AL, Williams R. Interleukin 2 activity in chronic liver disease and the effect of in vitro alpha-interferon. Clin Exp Immunol. 1986;63:541–548.
al-Wabel A, al-Janadi M, Raziuddin S. Cytokine profile of viral and autoimmune chronic active hepatitis. J Allergy Clin Immunol. 1993;92:902–908.
Czaja AJ, Sievers C, Zein NN. Nature and behavior of serum cytokines in type 1 autoimmune hepatitis. Dig Dis Sci. 2000;45:1028–1035.
Diestelhorst J, Junge N, Jonigk D et al. Baseline IL-2 and the AIH score can predict the response to standard therapy in paediatric autoimmune hepatitis. Sci Rep. 2018;8:419.
Yousefi A, Mahmoudi E, Baradaran Noveiry B et al. Autoimmune hepatitis association with single nucleotide polymorphism of interleukin-2, but not interferon-gamma. Clin Res Hepatol Gastroenterol. 2018;42:134–138.
Diestelhorst J, Junge N, Schlue J, et al. Pediatric autoimmune hepatitis shows a disproportionate decline of regulatory T cells in the liver and of IL-2 in the blood of patients undergoing therapy. PLoS One. 2017;12:e0181107.
Taubert R, Hardtke-Wolenski M, Noyan F et al. Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies. J Hepatol. 2014;61:1106–1114.
Longhi MS, Ma Y, Mitry RR et al. Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmun. 2005;25:63–71.
Longhi MS, Hussain MJ, Mitry RR et al. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol. 2006;176:4484–4491.
Peiseler M, Sebode M, Franke B et al. FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. J Hepatol. 2012;57:125–132.
Grant CR, Liberal R, Mieli-Vergani G, Vergani D, Longhi MS. Regulatory T-cells in autoimmune diseases: challenges, controversies and–yet–unanswered questions. Autoimmun Rev. 2015;14:105–116.
Liberal R, Grant CR, Holder BS et al. The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9/tim-3 pathway. Hepatology. 2012;56:677–686.
Schmidt B. Proof of Principle studies. Epilepsy Res. 2006;68:48–52.
Yang JC, Topalian SL, Parkinson D et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol. 1994;12:1572–1576.
Shulman KL, Stadler WM, Vogelzang NJ. High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience. Urology. 1996;47:194–197.
Dutcher JP, Schwartzentruber DJ, Kaufman HL et al. High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014. J Immunother Cancer. 2014;2:26.
Siddall E, Khatri M, Radhakrishnan J. Capillary leak syndrome: etiologies, pathophysiology, and management. Kidney Int. 2017;92:37–46.
Jeong GH, Lee KH, Lee IR et al. Incidence of capillary leak syndrome as an adverse effect of drugs in cancer patients: a systematic review and meta-analysis. J Clin Med. 2019;8:143.
Parameswaran R, Lim M, Fei F et al. Effector-mediated eradication of precursor B acute lymphoblastic leukemia with a novel Fc-engineered monoclonal antibody targeting the BAFF-R. Mol Cancer Ther. 2014;13:1567–1577.
Dorner T, Posch MG, Li Y et al. Treatment of primary Sjogren’s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Ann Rheum Dis. 2019;78:641–647.
McWilliams EM, Lucas CR, Chen T et al. Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib. Blood Adv. 2019;3:447–460.
Diekhoff T, Fischer T, Schefer Q et al. Ianalumab (VAY736) in primary Sjogren’s syndrome: assessing disease activity using multi-modal ultrasound. Clin Exp Rheumatol. 2020;38:228–236.
Baker KP, Edwards BM, Main SH et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48:3253–3265.
Samy E, Wax S, Huard B, Hess H, Schneider P. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int Rev Immunol. 2017;36:3–19.
Moore PA, Belvedere O, Orr A et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285:260–263.
Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104:487–501.
Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci. 2002;27:19–26.
Huard B, Arlettaz L, Ambrose C et al. BAFF production by antigen-presenting cells provides T cell co-stimulation. Int Immunol. 2004;16:467–475.
Nardelli B, Belvedere O, Roschke V et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood. 2001;97:198–204.
Scapini P, Nardelli B, Nadali G et al. G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med. 2003;197:297–302.
Scapini P, Carletto A, Nardelli B et al. Proinflammatory mediators elicit secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: implications for inflammatory diseases. Blood. 2005;105:830–837.
Hsu BL, Harless SM, Lindsley RC, Hilbert DM, Cancro MP. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol. 2002;168:5993–5996.
Thompson JS, Bixler SA, Qian F et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science. 2001;293:2108–2111.
Benson MJ, Dillon SR, Castigli E et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol. 2008;180:3655–3659.
Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol. 2009;9:491–502.
Kayagaki N, Yan M, Seshasayee D et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity. 2002;17:515–524.
Claudio E, Brown K, Park S, Wang H, Siebenlist U. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol. 2002;3:958–965.
Wu Y, Bressette D, Carrell JA et al. Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem. 2000;275:35478–35485.
Marsters SA, Yan M, Pitti RM et al. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol. 2000;10:785–788.
Gross JA, Johnston J, Mudri S et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000;404:995–999.
Darce JR, Arendt BK, Wu X, Jelinek DF. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol. 2007;179:7276–7286.
Figgett WA, Fairfax K, Vincent FB et al. The TACI receptor regulates T-cell-independent marginal zone B cell responses through innate activation-induced cell death. Immunity. 2013;39:573–583.
O’Connor BP, Raman VS, Erickson LD et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004;199:91–98.
Peperzak V, Vikstrom I, Walker J et al. Mcl-1 is essential for the survival of plasma cells. Nat Immunol. 2013;14:290–297.
Schiemann B, Gommerman JL, Vora K et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science. 2001;293:2111–2114.
Avery DT, Kalled SL, Ellyard JI et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest. 2003;112:286–297.
Rauch M, Tussiwand R, Bosco N, Rolink AG. Crucial role for BAFF-BAFF-R signaling in the survival and maintenance of mature B cells. PLoS One. 2009;4:e5456.
Do RK, Hatada E, Lee H et al. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med. 2000;192:953–964.
Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol. 2002;2:465–475.
Xu LG, Wu M, Hu J, Zhai Z, Shu HB. Identification of downstream genes up-regulated by the tumor necrosis factor family member TALL-1. J Leukoc Biol. 2002;72:410–416.
Xu LG, Shu HB. TNFR-associated factor-3 is associated with BAFF-R and negatively regulates BAFF-R-mediated NF-kappa B activation and IL-10 production. J Immunol. 2002;169:6883–6889.
Furie R, Stohl W, Ginzler EM et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008;10:R109.
Wallace DJ, Stohl W, Furie RA et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61:1168–1178.
Navarra SV, Guzman RM, Gallacher AE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721–731.
Furie R, Petri M, Zamani O et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918–3930.
Wise LM, Stohl W. The safety of belimumab for the treatment of systemic lupus erythematosus. Expert Opin Drug Saf. 2019;18:1133–1144.
Chatham W, Chadha A, Fettiplace J et al. A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus. Lupus. 2017;26:1483–1490.
Czaja AJ. Examining pathogenic concepts of autoimmune hepatitis for cues to future investigations and interventions. World J Gastroenterol. 2019;25:6579–6606.
Mascelli MA, Zhou H, Sweet R et al. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. J Clin Pharmacol. 2007;47:553–565.
Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov. 2007;6:349–356.
Rau R. Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis. 2002;61 Suppl 2:ii70–73.
Shealy DJ, Cai A, Staquet K et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs. 2010;2:428–439.
Clark M. Antibody humanization: a case of the “Emperor’s new clothes”? Immunol Today. 2000;21:397–402.
Kamimura D, Sawa Y, Sato M et al. IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb. J Immunol. 2006;177:306–314.
Kamimura D, Bevan MJ. Naive CD8+ T cells differentiate into protective memory-like cells after IL-2 anti IL-2 complex treatment in vivo. J Exp Med. 2007;204:1803–1812.
Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151–1164.
Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol. 2005;6:1142–1151.
Finkelman FD, Madden KB, Morris SC, et al. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol. 1993;151:1235–1244.
Letourneau S, van Leeuwen EM, Krieg C et al. IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. Proc Natl Acad Sci U S A. 2010;107:2171–2176.
Hahne M, Kataoka T, Schroter M et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med. 1998;188:1185–1190.
Stein JV, Lopez-Fraga M, Elustondo FA et al. APRIL modulates B and T cell immunity. J Clin Invest. 2002;109:1587–1598.
Yang M, Hase H, Legarda-Addison D et al. B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells. J Immunol. 2005;175:2814–2824.
Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol. 2003;21:231–264.
Ingold K, Zumsteg A, Tardivel A et al. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med. 2005;201:1375–1383.
Belnoue E, Pihlgren M, McGaha TL et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood. 2008;111:2755–2764.
Bossen C, Cachero TG, Tardivel A et al. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood. 2008;111:1004–1012.
Tai YT, Lin L, Xing L et al. APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. Leukemia. 2019;33:426–438.
Koyama T, Tsukamoto H, Miyagi Y et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis. 2005;64:1065–1067.
Hegazy M, Darwish H, Darweesh H, El-Shehaby A, Emad Y. Raised serum level of APRIL in patients with systemic lupus erythematosus: correlations with disease activity indices. Clin Immunol. 2010;135:118–124.
Huard B, Tran NL, Benkhoucha M, Manzin-Lorenzi C, Santiago-Raber ML. Selective APRIL blockade delays systemic lupus erythematosus in mouse. PLoS One. 2012;7:e31837.
Wang H, Marsters SA, Baker T et al. TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol. 2001;2:632–637.
Pelletier M, Thompson JS, Qian F et al. Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF. J Biol Chem. 2003;278:33127–33133.
Baldo BA. Chimeric fusion proteins used for therapy: indications, mechanisms, and safety. Drug Saf. 2015;38:455–479.
Cogollo E, Silva MA, Isenberg D. Profile of atacicept and its potential in the treatment of systemic lupus erythematosus. Drug Des Devel Ther. 2015;9:1331–1339.
Haselmayer P, Vigolo M, Nys J, Schneider P, Hess H. A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells. Eur J Immunol. 2017;47:1075–1085.
Czaja AJ. Immune inhibitory properties and therapeutic prospects of transforming growth factor-beta and interleukin 10 in autoimmune hepatitis. Dig Dis Sci. 2021. https://doi.org/10.1007/s10620-021-06968-6.
Vavricka SR, Bentele N, Scharl M et al. Systematic assessment of factors influencing preferences of Crohn’s disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL). Inflamm Bowel Dis. 2012;18:1523–1530.
Solitano V, Vuitton L, Peyrin-Biroulet L, Danese S. The evolution of biologics administration from intravenous to subcutaneous: treatments for inflammatory bowel disease go home. Gastroenterology. 2021;160:2244–2247.
Schreiber S, Ben-Horin S, Leszczyszyn J et al. Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease. Gastroenterology. 2021;160:2340–2353.
Stoner KL, Harder H, Fallowfield LJ, Jenkins VA. Intravenous versus subcutaneous drug administration. which do patients prefer? A systematic review. Patient. 2014.
Donahue ND, Acar H, Wilhelm S. Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. Adv Drug Deliv Rev. 2019;143:68–96.
Su C, Liu Y, Li R et al. Absorption, distribution, metabolism and excretion of the biomaterials used in nanocarrier drug delivery systems. Adv Drug Deliv Rev. 2019;143:97–114.
Zhu Y, Yu X, Thamphiwatana SD, Zheng Y, Pang Z. Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy. Acta Pharm Sin B. 2020;10:2054–2074.
van der Valk ME, Mangen MJ, Leenders M et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study. Gut. 2014;63:72–79.
McCamish M, Woollett G. Worldwide experience with biosimilar development. MAbs. 2011;3:209–217.
Mysler E, Pineda C, Horiuchi T et al. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. Rheumatol Int. 2016;36:613–625.
Bonek K, Roszkowski L, Massalska M, Maslinski W, Ciechomska M. Biologic drugs for rheumatoid arthritis in the context of biosimilars, genetics, epigenetics and COVID-19 treatment. Cells. 2021;10.
Azevedo VF. Biosimilars require scientifically reliable comparative clinical data. Rev Bras Reumatol. 2013;53:129–131.
Jorgensen KK, Olsen IC, Goll GL et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389:2304–2316.
Dorner T, Kay J. Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol. 2015;11:713–724.
Azevedo VF, Galli N, Kleinfelder A, D’Ippolito J, Urbano PC. Etanercept biosimilars. Rheumatol Int. 2015;35:197–209.
Cheifetz AS, Abreu MT, Afif W et al. A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease. Am J Gastroenterol. 2021;116:2014–2025.
Abdalla MI, Levesque BG. Progress in corticosteroid use in the era of biologics with room for improvement. Am J Gastroenterol. 2021;116:1187–1188.
Targownik LE, Bernstein CN, Benchimol EI et al. Trends in corticosteroid use during the era of biologic therapy: a population-based analysis. Am J Gastroenterol. 2021;116:1284–1293.
Funding
This review did not receive financial support from a funding agency or institution
Author information
Authors and Affiliations
Contributions
AJC, MD researched, designed, and wrote this article. The 4 tables and 3 color figures are original, constructed by Dr. Czaja, and developed solely for this review. The review article is original, current, and comprehensive, and it has not been published previously.
Corresponding author
Ethics declarations
Conflict of interest
Albert J. Czaja, MD has no conflict of interests to declare.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Czaja, A.J. Advancing Biologic Therapy for Refractory Autoimmune Hepatitis. Dig Dis Sci 67, 4979–5005 (2022). https://doi.org/10.1007/s10620-021-07378-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-021-07378-4